deltatrials
Terminated EARLY_PHASE1 INTERVENTIONAL 1-arm NCT03492164

In Vivo PARP-1 Expression With 18F-FTT PET/CT in Pancreatic Cancer

Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Pancreatic Cancer

Sponsor: Abramson Cancer Center at Penn Medicine

Conditions Pancreatic Cancer
Interventions [18F]FluorThanatrace ([18F]FTT)
Updated 13 times since 2018 Last updated: Jun 11, 2024 Started: Mar 20, 2018 Primary completion: Jun 11, 2024 Completion: Jun 11, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Early analysis of images after 6 patients showed no activity of the radiotracer in this patient population.

Other terminated trials from Abramson Cancer Center at Penn Medicine

See all terminations from Abramson Cancer Center at Penn Medicine

Other Pancreatic Cancer trials with similar outcome

Browse all Pancreatic Cancer trials

Listed as NCT03492164, this EARLY_PHASE1 trial focuses on Pancreatic Cancer and remains terminated or withdrawn. Sponsored by Abramson Cancer Center at Penn Medicine, it has been updated 13 times since 2018, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~May 2019 · 11 months · monthly snapshot~May 2019 – ~Apr 2020 · 11 months · monthly snapshot~Apr 2020 – ~Oct 2020 · 6 months · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Nov 2021 · 10 months · monthly snapshot~Nov 2021 – ~Jan 2023 · 14 months · monthly snapshot~Jan 2023 – ~Apr 2023 · 3 months · monthly snapshot~Apr 2023 – ~Aug 2023 · 4 months · monthly snapshot~Aug 2023 – ~May 2024 · 9 months · monthly snapshot~May 2024 – ~Jul 2024 · 2 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

13 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated EARLY_PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated EARLY_PHASE1

    Status: Active Not Recruiting → Terminated

  3. May 2024 — Jul 2024 [monthly]

    Active Not Recruiting EARLY_PHASE1

  4. Aug 2023 — May 2024 [monthly]

    Active Not Recruiting EARLY_PHASE1

    Status: Recruiting → Active Not Recruiting

  5. Apr 2023 — Aug 2023 [monthly]

    Recruiting EARLY_PHASE1

▶ Show 8 earlier versions

  1. Jan 2023 — Apr 2023 [monthly]

    Recruiting EARLY_PHASE1

  2. Nov 2021 — Jan 2023 [monthly]

    Recruiting EARLY_PHASE1

  3. Jan 2021 — Nov 2021 [monthly]

    Recruiting EARLY_PHASE1

  4. Oct 2020 — Jan 2021 [monthly]

    Recruiting EARLY_PHASE1

    Status: Active Not Recruiting → Recruiting

  5. Apr 2020 — Oct 2020 [monthly]

    Active Not Recruiting EARLY_PHASE1

    Status: Recruiting → Active Not Recruiting

  6. May 2019 — Apr 2020 [monthly]

    Recruiting EARLY_PHASE1

  7. Jun 2018 — May 2019 [monthly]

    Recruiting EARLY_PHASE1

  8. May 2018 — Jun 2018 [monthly]

    Recruiting EARLY_PHASE1

    First recorded

Mar 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Abramson Cancer Center at Penn Medicine
Data source: Abramson Cancer Center at Penn Medicine

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations